- World rank, 2022–2025
- #20,775 of 28,054 · #20,279 all time
- Rank in China
- #2,904 of 3,058
- Research works
- 227 ◆ 0% vs 2013–17
- Citations
- 5.7k 25.0 per fractional work
- Top-10% rate
- 15.7% record average 16.5%
- Open access
- 46% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 4.7×. Every wedge is a field page.
- Immunology and Microbiology 4.7×
- Pharmacology, Toxicology and Pharmaceutics 4.5×
- Nursing 3.8×
- Biochemistry, Genetics and Molecular Biology 3.0×
- Medicine 2.8×
- Chemistry 2.2×
- Mathematics 1.1×
- Economics, Econometrics and Finance 1.0×
- Health Professions 0.8×
- Decision Sciences 0.8×
- Materials Science 0.6×
- Dentistry 0.4×
- Chemical Engineering 0.4×
- Agricultural and Biological Sciences 0.4×
- Computer Science 0.3×
- Engineering 0.2×
- Earth and Planetary Sciences 0.2×
- Energy 0.1×
- Business, Management and Accounting 0.1×
- Environmental Science 0.1×
- Physics and Astronomy 0.1×
- Social Sciences 0.0×
Who are the top researchers at Roche (China)?
Ranked on the composite score, Hong C. Shen lead among researchers whose main affiliation is Roche (China).
- 1 Hong C. Shen China · #189,685 worldwide 171 citations · 25 works
Which keywords describe research at Roche (China)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Immune Response, PET Imaging, Lymphoma, Rituximab, Tumor Microenvironment, Targeted Therapy and Classification.
- Tumor Regression
- Hepatitis C Virus
- Staging System
- Diagnosis Criteria
- Cancer Immunotherapy
- ALK Inhibitors
- PD-1 and PD-L1
- Hepatitis B Virus
- Chronic Hepatitis B
- Global Burden
- Prognostic Factors
- Clinical Trials
- Liver Disease
- Antiviral Therapy
- Molecular Profiling
- Genetic Pathogenesis
- Targeted Therapy
- Rituximab
- Lymphoma
- Immune Response
- Chemotherapy
- PET Imaging
- Epidemiology
- Tumor Microenvironment
- Classification
- Hepatocellular Carcinoma
- Cancer Therapy
- Inflammation
- Immunotherapy
- Treatment
- Proteasome Inhibitors
- Angiogenesis
- Genetic Variation
- Immune Checkpoint Blockade
- Therapeutic Targets
- Breast Cancer
- EGFR Mutations
- International Myeloma Working Group
- Monoclonal Antibody
- Inhibitors
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy5▲ 10×14 topics
- Immune Response5▲ 13×9 topics
- PET Imaging4▲ 41×4 topics
- Lymphoma4▲ 39×2 topics
- Epidemiology4▲ 1.57×22 topics
- Rituximab4▲ 41×2 topics
- Tumor Microenvironment4▲ 13×7 topics
- Targeted Therapy4▲ 25×5 topics
- Classification3▲ 11×2 topics
- Genetic Pathogenesis3▲ 87×1 topic
- Hepatocellular Carcinoma3▲ 22×3 topics
- Molecular Profiling3▲ 47×1 topic
- Cancer Therapy3▲ 8.0×9 topics
- Antiviral Therapy3▲ 44×2 topics
- Inflammation3▲ 2.1×16 topics
- Liver Disease3▲ 48×3 topics
- Immunotherapy2▲ 5.5×11 topics
- Clinical Trials2▲ 5.5×4 topics
- Treatment2▲ 3.0×8 topics
- Prognostic Factors2▲ 8.1×5 topics
- Proteasome Inhibitors2▲ 42×2 topics
- Global Burden2▲ 5.2×4 topics
- Angiogenesis2▲ 7.8×3 topics
- Chronic Hepatitis B2▲ 74×1 topic
- Genetic Variation2▲ 12×2 topics
- Hepatitis B Virus2▲ 74×1 topic
- Immune Checkpoint Blockade2▲ 23×1 topic
- PD-1 and PD-L12▲ 23×1 topic
- Therapeutic Targets2▲ 17×4 topics
- ALK Inhibitors2▲ 37×1 topic
- Breast Cancer2▲ 9.8×3 topics
- Cancer Immunotherapy2▲ 15×3 topics
- EGFR Mutations2▲ 37×1 topic
- Diagnosis Criteria1▲ 61×1 topic
- International Myeloma Working Group1▲ 61×1 topic
- Staging System1▲ 36×2 topics
- Monoclonal Antibody1▲ 39×2 topics
- Hepatitis C Virus1▲ 54×1 topic
- Inhibitors1▲ 47×2 topics
- Tumor Regression1▲ 18×2 topics
Which research topics does Roche (China) publish most on?
By volume in 2022–2025: Lymphoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Hepatitis B Virus Studies and Lung Cancer Treatments and Mutations.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 3 works
- 2 Cancer Immunotherapy and Biomarkers Oncology 2 works
- 3 Hepatitis B Virus Studies Epidemiology 2 works
- 4 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
- 5 Multiple Myeloma Research and Treatments Hematology 1 works
- 6 Hepatitis C virus research Hepatology 1 works
- 7 HER2/EGFR in Cancer Research Oncology 1 works
- 8 CAR-T cell therapy research Oncology 1 works
- 9 Liver Disease Diagnosis and Treatment Epidemiology 1 works
- 10 Quality and Safety in Healthcare Medical Laboratory Technology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Roche (China)'s research output changed?
Output in 2018–2022 was 0% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Shanghai
- Shanghai Jiao Tong University
- Tongji University
- Fudan University
- Shanghai University
- East China Normal University
- East China University of Science and Technology
- Donghua University
- University of Shanghai for Science and Technology
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.